Search

In Stock

Buy Evkeeza (evinacumab) Online

DISEASE INDICATIONS: Hypercholesterolemia

MANUFACTURER: Regeneron Pharmaceuticals, Inc.

USAGE: Intravenous

MEDICINE APPROVED BY:

Food and Drug Administration (FDA)

Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.

This product is currently out of stock and unavailable.

Compare

Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.

Evkeeza is used in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare, inherited form of high cholesterol that can lead to serious health problems, including heart disease and stroke, at a young age.

Evkeeza works by blocking the activity of ANGPTL3. ANGPTL3 inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), two enzymes that break down fats in the blood. By blocking ANGPTL3, Evkeeza increases the activity of LPL and EL, which leads to a reduction in LDL-C levels.

Evkeeza is administered as a subcutaneous injection once every four weeks. The dosage is individualized based on the patient’s weight and response to treatment.

In clinical trials, Evkeeza was shown to be very effective in lowering LDL-C levels in patients with HoFH. In one study, Evkeeza reduced LDL-C levels by an average of 48% after 12 weeks of treatment. Evkeeza was also well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.

Evkeeza is a significant advance in the treatment of HoFH. It is the first effective treatment for this condition that is not associated with serious side effects. Evkeeza can help patients with HoFH to reduce their risk of heart disease, stroke, and other serious health problems.

Here are some additional details about Evkeeza:

  • It is a first-of-its-kind treatment for HoFH.
  • It is used in combination with other cholesterol-lowering medicines.
  • It is administered as a subcutaneous injection once every four weeks.
  • It has been shown to be very effective in lowering LDL-C levels in patients with HoFH.
  • It is well-tolerated, with the most common side effects being injection site reactions, fatigue, and headache.

Evkeeza is a promising new treatment for HoFH that can help patients to reduce their risk of heart disease, stroke, and other serious health problems.

Package

1 vial of 345 mg/2.3 mL (150 mg/mL), 1 vial of 1,200 mg/8 mL (150 mg/mL)

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Palynziq (pegvaliase-pqpz) Online

From $321.42
(0 Reviews)
DISEASE INDICATIONS: phenylketonuria (PKU) MANUFACTURER: BioMarin Pharmaceutical Inc. USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Palynziq (pegvaliase-pqpz) is a prescription medication used to lower blood levels of phenylalanine (Phe) in adults with phenylketonuria (PKU) who have uncontrolled blood Phe levels above 600 micromol/L (10 mg/dL) on their current treatment. PKU is a rare genetic disorder that prevents the body from breaking down the amino acid phenylalanine. Phenylalanine can build up in the blood and cause serious health problems, such as intellectual disability, seizures, and behavioral problems.

Buy Waylivra (volanesorsen) Online

$11,550.76
(0 Reviews)
DISEASE INDICATIONS: Familial chylomicronemia syndrome (FCS) MANUFACTURER: Akcea Therapeutics Ireland Limited USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Waylivra (volanesorsen) is a prescription medication used to treat adults with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. FCS is a rare genetic disorder that causes the body to produce too much of a type of fat called chylomicrons. Chylomicrons can build up in the blood and cause pancreatitis, a serious inflammation of the pancreas.

Buy Isturisa (osilodrostat) Online

From $1,818.17
(0 Reviews)
DISEASE INDICATIONS: Primary Biliary Cholangitis (PBC) MANUFACTURER: Novartis USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Isturisa (osilodrostat) is a cortisol synthesis inhibitor used to treat Cushing's syndrome, a condition in which the body produces too much of the hormone cortisol. It is approved by the US Food and Drug Administration (FDA) for adults with Cushing's disease, a type of Cushing's syndrome caused by a tumor on the pituitary gland, and for adults with endogenous Cushing's syndrome (ECS), a type of Cushing's syndrome caused by the body overproducing cortisol on its own.

Buy Zokinvy (lonafarnib) Online

From $31,401.66
(0 Reviews)
DISEASE INDICATIONS: Progeria MANUFACTURER: Eiger Biopharmaceuticals USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Zokinvy (lonafarnib) is a prescription medication used to treat Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL) in children aged 12 months and older. HGPS and PDPL are rare genetic disorders that cause premature aging.

Buy Oxlumo (lumasiran) Online

$64,110.43
(0 Reviews)
DISEASE INDICATIONS: Primary hyperoxaluria type 1 (PH1) MANUFACTURER: Alnylam Pharmaceuticals USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Oxlumo (lumasiran) is a prescription medicine used to treat primary hyperoxaluria type 1 (PH1) in children and adults. PH1 is a rare genetic disorder that causes the body to produce too much of a substance called oxalate. Oxaluria can cause kidney stones, damage to the kidneys and other organs, and even death.

Buy Leqvio (inclisiran) Online

$2,671.00
(0 Reviews)
DISEASE INDICATIONS: Hypercholesterolemia MANUFACTURER: Novartis USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Kerendia (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Buy Evkeeza (evinacumab) Online

(0 Reviews)
DISEASE INDICATIONS: Hypercholesterolemia MANUFACTURER: Regeneron Pharmaceuticals, Inc. USAGE: Intravenous MEDICINE APPROVED BY: Food and Drug Administration (FDA) Evkeeza (evinacumab) is a fully human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. It is the first FDA-approved treatment that binds to and blocks the function of ANGPTL3.

Back to Top
Product has been added to your cart